

REMARKS

In the Office Action, the sole pending claim 20 has been allowed. However, the Patent Office has requested a new sequence listing based on proposed changes to the previously-submitted sequence listing and drawings that references sequences therein as recited in Applicants' amendment filed on August 19, 2002.

In response, Applicants are submitting herewith a copy of a substitute sequence listing (Exhibit 1) that includes the changes to the sequences as discussed above. Applicants note for the record that the proposed changes have been accepted by the Patent Office as indicated in the Office Action dated November 21, 2003 on page 2. Applicants note that a print copy of the substitute sequence listing is attached herewith and further that an amendment directing its entry into the specification has been made as previously discussed. Applicants further note that they are concurrently submitting herewith a separate submission of the substitute sequence listing that includes the print copy as submitted herewith in addition to a copy in computer-readable form. Applicants state that the content of the paper and the computer-readable form copies of the substitute sequence listing are the same and further believe that no new matter has been added thereby. Accordingly, Applicants respectfully submit that the requirements pursuant to 37 C.F.R. § 1.821-1.825 have been satisfied.

Applicants note for the record than an Office Action was previously mailed on June 17, 2003 ("Office Action") regarding the above-identified patent application. A copy of the Office Action is attached herewith as Exhibit 2. The Office Action is essentially the same as the Office Action that was submitted on November 21, 2003. In this regard, it is Applicants' understanding that the Applicants are only required to respond to the Office Action dated November 21, 2003 based on a discussion regarding same between Examiner Jennifer Graser and Thomas C. Basso, the undersigned attorney of record.

However, to the extent that the Office Action is still in effect and thus requires a response thereto, Applicants respectfully submit that this amendment should also be deemed responsive to the Office Action mailed June 17, 2003 and further request that if any fees due in connection with same and this application as a whole be deducted from Deposit Account No. 02-1818. If such a withdrawal is made, please indicate the Attorney Docket No. (113190-064) on the account statement.

For the foregoing reasons, Applicants believe that the present application is in condition for allowance and earnestly solicit reconsideration of same.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Thomas C. Basso
Reg. No. 46,541
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4310

Dated: December 17, 2003

SEQUENCE LISTING

<110> Irvin, Randall T.
Hodges, Robert S.

<120> Pseudomonas Treatment Composition and Method

<130> 0113190-00064

<140> US 09/865,159
<141> 2003-03-01

<150> US 09/329,884
<151> 1999-06-11

<150> US 60/089,155
<151> 1998-06-12

<160> 22

<170> PatentIn version 3.1

<210> 1
<211> 387
<212> DNA
<213> Pseudomonas aeruginosa

<400> 1
gcgctcgagg gtaccgaatt cgcacgcgt cagcttagcg aacgcattgac cctggccagt 60
ggtctcaaga cgaaaagttag cgatatcttc ttcaggatgt ggtcctgccg ggctaataact 120
gctgccacgg caggcatcga gaaagatacc gacatcaacg gcaagttatgt tgccaaggta 180
acaactggtg gcacccgcgc tgcgtctggt ggttgcacta tcgttgctac tatgaaagcc 240
tctgatgtgg ctactcctct gagggggaaa actctgactt tgactctagg aaatgctgac 300
aagggttctt acacttgggc ctgtacttcc aacgcagata acaagtacct gccaaaaacc 360
tgccagactg ctaccactac cactccg 387

<210> 2
<211> 129
<212> PRT
<213> Pseudomonas aeruginosa

<400> 2

Ala Leu Glu Gly Thr Glu Phe Ala Arg Ala Gln Leu Ser Glu Arg Met
1 5 10 15

Thr Leu Ala Ser Gly Leu Lys Thr Lys Val Ser Asp Ile Phe Ser Gln
20 25 30

Asp Gly Ser Cys Pro Ala Asn Thr Ala Ala Thr Ala Gly Ile Glu Lys
35 40 45

Asp Thr Asp Ile Asn Gly Lys Tyr Val Ala Lys Val Thr Thr Gly Gly
50 55 60

Thr Ala Ala Ala Ser Gly Gly Cys Thr Ile Val Ala Thr Met Lys Ala
65 70 75 80

Ser Asp Val Ala Thr Pro Leu Arg Gly Lys Thr Leu Thr Leu Thr Leu
85 90 95

Gly Asn Ala Asp Lys Gly Ser Tyr Thr Trp Ala Cys Thr Ser Asn Ala
100 105 110

Asp Asn Lys Tyr Leu Pro Lys Thr Cys Gln Thr Ala Thr Thr Thr Thr
115 120 125

Pro

<210> 3
<211> 369
<212> DNA
<213> Pseudomonas aeruginosa

<400> 3

gcgctcgagg gtaccgaatt cgctcggtcg gaaggcgcat ctgctttgc ttcggtaat
60

ccgttgaaga ctaccgttga agaggcgctt tctcgtggtt ggagcgtgaa gagcggta
120

ggtacagagg acgctactaa gaaagagggtt cctctggggg tggcggcaga tgctaacaaa
180

ctgggtacta tcgcactcaa acccgatcct gctgatggta ctgcagatat cactttgact
240

ttcaactatgg gcgggtgcagg accgaagaat aaaggaaaa ttattaccct gactcgtact
300

gcagctgatg gtctctggaa gtgcaccagt gatcaggatg agcagtttat tccgaaaggt
360

tgctcttagg
369

<210> 4
 <211> 123
 <212> PRT
 <213> Pseudomonas aeruginosa

<400> 4

Ala	Leu	Glu	Gly	Thr	Glu	Phe	Ala	Arg	Ser	Glu	Gly	Ala	Ser	Ala	Leu
1				5					10						15

Ala	Ser	Val	Asn	Pro	Leu	Lys	Thr	Thr	Val	Glu	Glu	Ala	Leu	Ser	Arg
					20			25						30	

Gly	Trp	Ser	Val	Lys	Ser	Gly	Thr	Gly	Thr	Glu	Asp	Ala	Thr	Lys	Lys
					35			40					45		

Glu	Val	Pro	Leu	Gly	Val	Ala	Ala	Asp	Ala	Asn	Lys	Leu	Gly	Thr	Ile
					50			55				60			

Ala	Leu	Lys	Pro	Asp	Pro	Ala	Asp	Gly	Thr	Ala	Asp	Ile	Thr	Leu	Thr
					65			70			75		80		

Phe	Thr	Met	Gly	Gly	Ala	Gly	Pro	Lys	Asn	Lys	Gly	Lys	Ile	Ile	Thr
							85		90				95		

Leu	Thr	Arg	Thr	Ala	Ala	Asp	Gly	Leu	Trp	Lys	Cys	Thr	Ser	Asp	Gln
					100			105				110			

Asp	Gln	Gln	Phe	Ile	Pro	Lys	Gly	Cys	Ser	Arg					
					115			120							

<210> 5
 <211> 366
 <212> DNA
 <213> Pseudomonas aeruginosa

<400> 5

gcgctcgagg	gtaccgaatt	cgcgcgttcg	gaaggtgctt	cggcgctggc	gacgatcaac	60
ccgctgaaga	ccactgttga	agagtgcgtg	tgcgcgtggaa	ttgctggtag	caaaaattaaa	120
atggtaacta	ctgcttctac	tgcgaccgaa	acatatgccg	gcgtcgagcc	ggatgccaac	180
aagttgggtg	taattgctgt	agcaatcgaa	gatagtggtg	cgggtgatat	tacctttacc	240
ttccagactg	gtacctctag	tcccaagaat	gctactaaag	ttatcactct	gaaccgtact	300
gcggatgggg	tctgggcttg	taaatctacc	caggatccga	tgttcactcc	gaaaggttgt	360
						366
	gataac					

<210> 6
 <211> 122
 <212> PRT
 <213> Pseudomonas aeruginosa

<400> 6

Ala	Leu	Glu	Gly	Thr	Glu	Phe	Ala	Arg	Ser	Glu	Gly	Ala	Ser	Ala	Leu
1				5					10						15

Ala	Thr	Ile	Asn	Pro	Leu	Lys	Thr	Thr	Val	Glu	Glu	Ser	Leu	Ser	Arg
				20				25							30

Gly	Ile	Ala	Gly	Ser	Lys	Ile	Lys	Ile	Gly	Thr	Thr	Ala	Ser	Thr	Ala
				35			40				45				

Thr	Glu	Thr	Tyr	Ala	Gly	Val	Glu	Pro	Asp	Ala	Asn	Lys	Leu	Gly	Val
				50			55					60			

Ile	Ala	Val	Ala	Ile	Glu	Asp	Ser	Gly	Ala	Gly	Asp	Ile	Thr	Phe	Thr
				65			70				75				80

Phe	Gln	Thr	Gly	Thr	Ser	Ser	Pro	Lys	Asn	Ala	Thr	Lys	Val	Ile	Thr
				85				90							95

Leu	Asn	Arg	Thr	Ala	Asp	Gly	Val	Trp	Ala	Cys	Lys	Ser	Thr	Gln	Asp
				100				105				110			

Pro	Met	Phe	Thr	Pro	Lys	Gly	Cys	Asp	Asn						
				115			120								

<210> 7
 <211> 381
 <212> DNA
 <213> Pseudomonas aeruginosa

<400> 7

gcgctcgagg	gtaccgaatt	cggccgtacc	caggtgaccc	gtgccgtgag	tgaagtca	60
gcgctgaaga	ccgctcgga	gtcggcgatt	ctggaaggga	aggagattgt	ttccagcgc	120
actcctaaag	atacccagta	tgacattggc	ttcacccgagt	ctacttgct	agatggttct	180
ggtaagagtc	agatccaggt	aacggacaat	aaagatggca	ccgtttaggtt	gtcgctacc	240
ttgggttaat	cttctggttc	cgccatcaa	ggggctgtaa	tcactgtttc	gcgtaaaaat	300
gacggagtct	ggaactgcaa	aatcacaaa	actcctacag	cttggaaagcc	caactacgct	360
ccggctaatt	gcccgaaattc	c				381

<210> 8
<211> 127
<212> PRT
<213> Pseudomonas aeruginosa

<400> 8

Ala Leu Glu Gly Thr Glu Phe Ala Arg Thr Gln Val Thr Arg Ala Val
1 5 10 15

Ser Glu Val Ser Ala Leu Lys Thr Ala Ala Glu Ser Ala Ile Leu Glu
20 25 30

Gly Lys Glu Ile Val Ser Ser Ala Thr Pro Lys Asp Thr Gln Tyr Asp
35 40 45

Ile Gly Phe Thr Glu Ser Thr Leu Leu Asp Gly Ser Gly Lys Ser Gln
50 55 60

Ile Gln Val Thr Asp Asn Lys Asp Gly Thr Val Glu Leu Val Ala Thr
65 70 75 80

Leu Gly Lys Ser Ser Gly Ser Ala Ile Lys Gly Ala Val Ile Thr Val
85 90 95

Ser Arg Lys Asn Asp Gly Val Trp Asn Cys Lys Ile Thr Lys Thr Pro
100 105 110

Thr Ala Trp Lys Pro Asn Tyr Ala Pro Ala Asn Cys Pro Asn Ser
115 120 125

<210> 9
<211> 381
<212> DNA
<213> Pseudomonas aeruginosa

<400> 9

gcgctcgagg gtaccgaatt ctctcgctct caggtctcca gggttatggc ggaggctggc 60
tccttgaaga ctgcagttga ggcctgcctc caggatggtc gtactgctgt gggtactgct 120
gctggtaat gcgatccggg tgcgacgggt tccagtttgt tgactgggtgc ttctcagact 180
tctcaaacctc tgccaaccaa taccggtgtt ccgcaggttc tggatcctct gactactcaa 240
accactatca ttgcgacttt tggtaacggc gcatccgcag ctatttctgg ccagactctg 300
acctggactc gtgatgttaa tggtggtgg agctgtgcta ctaccgtaga tgctaaattc 360
cgtcctaatg gctgtactga c 381

<210> 10
 <211> 127
 <212> PRT
 <213> Pseudomonas aeruginosa

<400> 10

Ala	Leu	Glu	Gly	Thr	Glu	Phe	Ser	Arg	Ser	Gln	Val	Ser	Arg	Val	Met
1				5				10					15		

Ala	Glu	Ala	Gly	Ser	Leu	Lys	Thr	Ala	Val	Glu	Ala	Cys	Leu	Gln	Asp
				20				25					30		

Gly	Arg	Thr	Ala	Val	Gly	Thr	Ala	Ala	Gly	Gln	Cys	Asp	Pro	Gly	Ala
					35			40			45				

Thr	Gly	Ser	Ser	Leu	Leu	Thr	Gly	Ala	Ser	Gln	Thr	Ser	Gln	Thr	Leu
					50		55			60					

Pro	Thr	Asn	Thr	Gly	Val	Pro	Gln	Val	Leu	Asp	Pro	Leu	Thr	Thr	Gln
					65		70		75			80			

Thr	Thr	Ile	Ile	Ala	Thr	Phe	Gly	Asn	Gly	Ala	Ser	Ala	Ile	Ser	
					85			90			95				

Gly	Gln	Thr	Leu	Thr	Trp	Thr	Arg	Asp	Val	Asn	Gly	Gly	Trp	Ser	Cys
					100			105			110				

Ala	Thr	Thr	Val	Asp	Ala	Lys	Phe	Arg	Pro	Asn	Gly	Cys	Thr	Asp	
					115			120			125				

<210> 11
 <211> 507
 <212> DNA
 <213> Pseudomonas aeruginosa

<400> 11

gcgctcgagc	accatcatca	ccatggtgtt	ggtggcgaga	ttgaggccct	caaggctgaa	60
atcgaagccc	taaaggccga	gatagaagca	cttaaggcag	agatcgaggc	gctaaaagcg	120
gaaatagagg	ctctgaaggc	aggcggtgga	ggagaattcg	ctcggtcgga	aggcgcacatc	180
gctcttgctt	cggtaatcc	gttgaagact	accgttgaag	aggcgctttc	tcgtgggttg	240
agcgtgaaga	gcggtacagg	tacagaggac	gtctactaaga	aagaggttcc	tctgggggtg	300
gcggcagatg	ctaacaaact	gggtactatac	gcactcaaac	ccgatcctgc	tgatggtact	360
gcagatatca	cttgacttt	cactatgggc	ggtgcaggac	cgaagaataa	agggaaaaatt	420
attaccctga	ctcgtaatgc	agctgatggt	ctctggaagt	gcaccagtga	tcaggatgag	480
cagtttattc	cgaaagttt	ctcttagg				507

<210> 12
 <211> 169
 <212> PRT
 <213> Pseudomonas aeruginosa

<400> 12

Ala	Leu	Glu	His	His	His	His	Gly	Gly	Gly	Gly	Glu	Ile	Glu	Ala
1							5		10			15		

Leu	Lys	Ala	Glu	Ile	Glu	Ala	Leu	Lys	Ala	Glu	Ile	Glu	Ala	Leu	Lys
				20				25				30			

Ala	Glu	Ile	Glu	Ala	Leu	Lys	Ala	Glu	Ile	Glu	Ala	Leu	Lys	Ala	Gly
				35				40				45			

Gly	Gly	Gly	Glu	Phe	Ala	Arg	Ser	Glu	Gly	Ala	Ser	Ala	Leu	Ala	Ser
				50			55		60						

Val	Asn	Pro	Leu	Lys	Thr	Thr	Val	Glu	Glu	Ala	Leu	Ser	Arg	Gly	Trp
				65			70		75				80		

Ser	Val	Lys	Ser	Gly	Thr	Gly	Thr	Glu	Asp	Ala	Thr	Lys	Lys	Glu	Val
				85				90				95			

Pro	Leu	Gly	Val	Ala	Ala	Asp	Ala	Asn	Lys	Leu	Gly	Thr	Ile	Ala	Leu
				100				105				110			

Lys	Pro	Asp	Pro	Ala	Asp	Gly	Thr	Ala	Asp	Ile	Thr	Leu	Thr	Phe	Thr
				115				120			125				

Met	Gly	Gly	Ala	Gly	Pro	Lys	Asn	Lys	Gly	Lys	Ile	Ile	Thr	Leu	Thr
				130				135			140				

Arg	Thr	Ala	Ala	Asp	Gly	Leu	Trp	Lys	Cys	Thr	Ser	Asp	Gln	Asp	Glu
				145				150			155		160		

Gln	Phe	Ile	Pro	Lys	Gly	Cys	Ser	Arg							
								165							

<210> 13
 <211> 507
 <212> DNA
 <213> Pseudomonas aeruginosa

<400> 13

gcgctcgagc	accatcatca	ccatggtggt	ggtgtggcagg	tatccgcttt	agagaaaagaa	60
gtttctgctc	tcgaaaaaaga	ggtcagtgtct	ctggaaaaag	aggtgtcagc	cttggaaaaag	120
gaagtatcat	cacttgagaa	gggcgggtgga	ggagaattcg	ctcggtcgga	aggcgcatct	180
gctttgtctt	cggtaatcc	gttgaagact	accgttgaag	aggcgctttc	tcgtggttgg	240
agcgtgaaga	gcggtagcagg	tacagaggac	gctactaaga	aagaggttcc	tctgggggtg	300
gcggcagatg	ctaacaact	gggtactatc	gcactcaaac	ccgatcctgc	tgatggtaact	360
gcagatatca	cttgacttt	cactatggc	ggtgcaggac	cgaagaataa	aggaaaatt	420
attaccctga	ctcgtaactgc	agctgatggt	ctctggaagt	gcaccagtga	tcaggatgag	480
cagtttattc	cgaaaggttg	ctcttagg				507

<210> 14
<211> 169
<212> PRT
<213> *Pseudomonas aeruginosa*

<400> 14

```

Ala Leu Glu His His His His Gly Gly Gly Gly Glu Val Ser Ala
1           5           10          15

```

Leu Glu Lys Glu Val Ser Ala Leu Glu Lys Glu Val Ser Ala Leu Glu
20 25 30

Lys Glu Val Ser Ala Leu Glu Lys Glu Val Ser Ala Leu Glu Lys Gly
35 40 45

Gly Gly Gly Glu Phe Ala Arg Ser Glu Gly Ala Ser Ala Leu Ala Ser
 50 55 60

Val	Asn	Pro	Leu	Lys	Thr	Thr	Val	Glu	Glu	Ala	Leu	Ser	Arg	Gly	Trp
65					70				75					80	

Ser Val Lys Ser Gly Thr Gly Thr Glu Asp Ala Thr Lys Lys Glu Val
85 90 95

Pro Leu Gly Val Ala Ala Asp Ala Asn Lys Leu Gly Thr Ile Ala Leu
100 105 110

Lys Pro Asp Pro Ala Asp Gly Thr Ala Asp Ile Thr Leu Thr Phe Thr
115 120 125

Met Gly Gly Ala Gly Pro Lys Asn Lys Gly Lys Ile Ile Thr Leu Thr
130 135 140

Arg Thr Ala Ala Asp Gly Leu Trp Lys Cys Thr Ser Asp Gln Asp Glu
145 150 155 160

Gln Phe Ile Pro Lys Gly Cys Ser Arg
165

<210> 15
<211> 525
<212> DNA
<213> *Pseudomonas aeruginosa*

<400> 15

gcgctcgagc accatcatca ccatgggtgt ggtggcgaga ttgaggccct caaggctgaa	60
atcgaagccc taaaaggccga gatagaagca cttaaggcag agatcgaggc gctaaaagcg	120
gaaatagagg ctctgaaggc aggcggtgga ggagaattcg cacgcgctca gcttagcgaa	180
cgcattgaccc tgccactgg tctcaagacg aaagtggcg atatcttctc tcaggatggg	240
tcctgccccgg ctaatactgc tgccacggca ggcattcgaga aagataccga catcaacggc	300
aagtatgttg ccaaggtaac aactgggtggc accgcagctg cgtctgggtt ttgcactatc	360
gttgctacta tgaaaaggcctc tgatgtggct actcctctga gggggaaaac tctgactttg	420
actcttaggaa atgctgacaa gggttttac acttgggcgt gtacttccaa cgccagataac	480
aagtacctgc caaaaacctgc ccagactgct accactacca ctcccg	525

<210> 16
<211> 175
<212> PRT
<213> Pseudomonas aeruginosa

<400> 16

Ala Leu Glu His His His His Gly Gly Gly Gly Glu Ile Glu Ala
1 5 10 15

Leu Lys Ala Glu Ile Glu Ala Leu Lys Ala Glu Ile Glu Ala Leu Lys
20 25 30

Ala Glu Ile Glu Ala Leu Lys Ala Glu Ile Glu Ala Leu Lys Ala Gly
35 40 45

Gly Gly Gly Glu Phe Ala Arg Ala Gln Leu Ser Glu Arg Met Thr Leu
50 55 60

Ala Ser Gly Leu Lys Thr Lys Val Ser Asp Ile Phe Ser Gln Asp Gly
65 70 75 80

Ser Cys Pro Ala Asn Thr Ala Ala Thr Ala Gly Ile Glu Lys Asp Thr
85 90 95

Asp Ile Asn Gly Lys Tyr Val Ala Lys Val Thr Thr Gly Gly Thr Ala
100 105 110

Ala Ala Ser Gly Gly Cys Thr Ile Val Ala Thr Met Lys Ala Ser Asp
115 120 125

Val Ala Thr Pro Lys Arg Gly Lys Thr Leu Thr Leu Thr Leu Gly Asn
130 135 140

Ala Asp Lys Gly Ser Thr Thr Trp Ala Cys Thr Ser Asn Ala Asp Asn
145 150 155 160

Lys Tyr Leu Pro Lys Thr Cys Gln Thr Ala Thr Thr Thr Pro
165 170 175

<210> 17
<211> 525
<212> DNA
<213> Pseudomonas aeruginosa

<400> 17

gcgctcgagc accatcatca ccatgggtgg tttggcgagg tatccgcgtt agagaaaga
gtttctgctc tcgaaaaaga ggtcagtgtct ctggaaaaag aggtgtcagc cttggaaaag
gaagtatcag cacttgagaa gggcggtgga ggagaattcg cacgcgccta gcttagcga
cgcatgaccc tggccagtgg tctcaagacg aaagtgagcg atatcttc tcaggatgg
tcctgcccg ctaatactgc tgccacggca ggcatacgaga aagataccga catcaacg
aagtatgttg ccaaggtaac aactgggtgc accgcagctg cgtctggtgg ttgcactatc
gttgctacta tgaaaggctc tggatgtggct actcctctga gggggaaaac tctgacttt
actcttaggaa atgttgacaa gggttttac acttgggcct gtacttccaa cgccagataac
aagtacatgc caaaaacctg ccagactgct accactacca ctccg 60
120
180
240
300
360
420
480
525

<210> 18
 <211> 175
 <212> PRT
 <213> Pseudomonas aeruginosa

<400> 18

Ala	Leu	Glu	His	His	His	His	Gly	Gly	Gly	Glu	Val	Ser	Ala		
1													15		
Leu	Glu	Lys	Glu	Val	Ser	Ala	Leu	Glu	Lys	Glu	Val	Ser	Ala	Leu	Glu
		20						25					30		
Lys	Glu	Val	Ser	Ala	Leu	Glu	Lys	Glu	Val	Ser	Ala	Leu	Glu	Lys	Gly
			35				40						45		
Gly	Gly	Gly	Glu	Phe	Ala	Arg	Ala	Gln	Leu	Ser	Glu	Arg	Met	Thr	Leu
			50			55						60			
Ala	Ser	Gly	Leu	Lys	Thr	Lys	Val	Ser	Asp	Ile	Phe	Ser	Gln	Asp	Gly
65				70					75					80	
Ser	Cys	Pro	Ala	Asn	Thr	Ala	Ala	Thr	Ala	Gly	Ile	Glu	Lys	Asp	Thr
				85				90					95		
Asp	Ile	Asn	Gly	Lys	Tyr	Val	Ala	Lys	Val	Thr	Thr	Gly	Gly	Thr	Ala
				100				105					110		
Ala	Ala	Ser	Gly	Gly	Cys	Thr	Ile	Val	Ala	Thr	Met	Lys	Ala	Ser	Asp
		115					120					125			
Val	Ala	Thr	Pro	Leu	Arg	Gly	Lys	Thr	Leu	Thr	Leu	Thr	Leu	Gly	Asn
			130			135				140					
Ala	Asp	Lys	Gly	Ser	Tyr	Thr	Trp	Ala	Cys	Thr	Ser	Asn	Ala	Asp	Asn
		145			150				155				160		
Lys	Tyr	Leu	Pro	Lys	Thr	Cys	Gln	Thr	Ala	Thr	Thr	Thr	Thr	Pro	
			165					170					175		

<210> 19
 <211> 504
 <212> DNA
 <213> Pseudomonas aeruginosa

<400> 19

```

gcgctcgagc accatcatca ccatgggtt ggtggcgaga ttgaggccct caaggctgaa 60
atcgaagccc taaaggccg aatagaagca cttaaaggcag agatcgaggc gctaaaagcg 120
gaaatagagg ctctgaaggc aggcggtgga ggagaattcg cgcgttcgga aggtgcttcg 180
gcgctggcga ccatcaaccc gctgaagacc actgttgaag agtcgctgtc gcgtggaaatt 240
gctggtagca aaattaaaaat tggtaactact gcttctactg cgaccgaaac atatgcggc 300
gtcgagccgg atgccaacaa gttgggtta attgctgtag caatcgaaga tagtggtgcg 360
ggtgatatta cccttacctt ccagactggt acctctagtc ccaagaatgc tactaaagtt 420
atcactctga accgtactgc ggtatgggtc tgggcttcta aatctaccca ggatccgatg 480
ttcactccga aaggttgtga taac 504
  
```

<210> 20
<211> 168
<212> PRT
<213> Pseudomonas aeruginosa

<400> 20

Ala Leu Glu His His His His Gly Gly Gly Gly Glu Ile Glu Ala
1 5 10 15

Leu Lys Ala Glu Ile Glu Ala Leu Lys Ala Glu Ile Glu Ala Leu Lys
20 25 30

Ala Glu Ile Glu Ala Leu Lys Ala Glu Ile Glu Ala Leu Lys Ala Gly
35 40 45

Gly Gly Gly Glu Phe Ala Arg Ser Glu Gly Ala Ser Ala Leu Ala Thr
50 55 60

Ile Asn Pro Leu Lys Thr Thr Val Glu Glu Ser Leu Ser Arg Gly Ile
65 70 75 80

Ala Gly Ser Lys Ile Lys Ile Gly Thr Thr Ala Ser Thr Ala Thr Glu
85 90 95

Thr Tyr Ala Gly Val Glu Pro Asp Ala Asn Lys Leu Gly Val Ile Ala
100 105 110

Val Ala Ile Glu Asp Ser Gly Ala Gly Asp Ile Thr Phe Thr Phe Gln
115 120 125

Thr Gly Thr Ser Ser Pro Lys Asn Ala Thr Lys Val Ile Thr Leu Asn
130 135 140

Arg Thr Ala Asp Gly Val Trp Ala Cys Lys Ser Thr Gln Asp Pro Met
145 150 155 160

Phe Thr Pro Lys Gly Cys Asp Asn
165

<210> 21
<211> 504
<212> DNA
<213> Pseudomonas aeruginosa

<400> 21

gcgctcgagc accatcatca ccatgggt ggtggcgagg tatccgcgtt agagaaaaga 60
gtttctgctc tcgaaaaaga ggtcagtgtct ctggaaaaag aggtgtcagc cttggaaaaag 120
gaagtatcag cacttgagaa gggcggtgga ggagaattcg cgcgatcgaa aggtgcttcg 180
gcgctggcga cgatcaaccc gctgaagacc actgttgaag agtcgtgtc gcgtggaaatt 240
gctggtagca aaattaaaaat tggtactact gcttctactg cgaccgaaac atatgccgc 300
gtcgagccgg atgccaacaa gttgggtgta attgctgttag caatcgaaga tagtggtgcg 360
ggtgatatta cctttacctt ccagactggt acctctagtc ccaagaatgc tactaaagtt 420
atcactctga accgtactgc ggatggggtc tgggcttgc aatctaccca ggatcccgatg 480
ttcactccga aagggttgtga taac 504

<210> 22
<211> 168
<212> PRT
<213> Pseudomonas aeruginosa

<400> 22

Ala Leu Glu His His His His Gly Gly Gly Gly Glu Val Ser Ala
1 5 10 15

Leu Glu Lys Glu Val Ser Ala Leu Glu Lys Glu Val Ser Ala Leu Glu
20 25 30

Lys Glu Val Ser Ala Leu Glu Lys Glu Val Ser Ala Leu Glu Lys Gly
35 40 45

Gly Gly Gly Glu Phe Ala Arg Ser Glu Gly Ala Ser Ala Leu Ala Thr
50 55 60

Ile Asn Pro Leu Lys Thr Thr Val Glu Glu Ser Leu Ser Arg Gly Ile
65 70 75 80

Ala Gly Ser Lys Ile Lys Ile Gly Thr Thr Ala Ser Thr Ala Thr Glu
85 90 95

Thr Tyr Ala Gly Val Glu Pro Asp Ala Asn Lys Leu Gly Val Ile Ala
100 105 110

Val Ala Ile Glu Asp Ser Gly Ala Gly Asp Ile Thr Phe Thr Phe Gln
115 120 125

Thr Gly Thr Ser Ser Pro Lys Asn Ala Thr Lys Val Ile Thr Leu Asn
130 135 140

Arg Thr Ala Asp Gly Val Trp Ala Cys Lys Ser Thr Gln Asp Pro Met
145 150 155 160

Phe Thr Pro Lys Gly Cys Asp Asn
165



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/865,159	05/24/2001	Randall T. Irvin	113190-064	3428
24573	7590	06/17/2003		
BELL, BOYD & LLOYD, LLC			EXAMINER	
PO BOX 1135				GRASER, JENNIFER E
CHICAGO, IL 60690-1135			ART UNIT	PAPER NUMBER

1645

DATE MAILED: 06/17/2003

DUE: 9-17-63

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED
BELL, BOYD & LLOYD
INTELLECTUAL PROPERTY DOCKET

JUN 23 2003

ATTY: RMB - TC/B
DOCKET #: 113190-064

Office Action Summary	Application No. 09/865,159	Applicant(s) Irvin et al.
	Examiner Jennifer Graser	Art Unit 1645
		
<i>-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --</i>		
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. <ul style="list-style-type: none"> - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 		
Status <p>1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>RCE & Response, 6/10/03</u></p> <p>2a) <input type="checkbox"/> This action is FINAL. 2b) <input checked="" type="checkbox"/> This action is non-final.</p> <p>3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11; 453 O.G. 213.</p>		
Disposition of Claims <p>4) <input checked="" type="checkbox"/> Claim(s) <u>20</u> is/are pending in the application.</p> <p>4a) Of the above, claim(s) _____ is/are withdrawn from consideration.</p> <p>5) <input checked="" type="checkbox"/> Claim(s) <u>20</u> is/are allowed.</p> <p>6) <input type="checkbox"/> Claim(s) _____ is/are rejected.</p> <p>7) <input type="checkbox"/> Claim(s) _____ is/are objected to.</p> <p>8) <input type="checkbox"/> Claims _____ are subject to restriction and/or election requirement.</p>		
Application Papers <p>9) <input type="checkbox"/> The specification is objected to by the Examiner.</p> <p>10) <input type="checkbox"/> The drawing(s) filed on _____ is/are objected to by the Examiner.</p> <p>11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved.</p> <p>12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.</p>		
Priority under 35 U.S.C. § 119 <p>13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).</p> <p>a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of:</p> <ol style="list-style-type: none"> 1. <input type="checkbox"/> Certified copies of the priority documents have been received. 2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____. 3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). <p>*See the attached detailed Office action for a list of the certified copies not received.</p> <p>14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).</p>		
Attachment(s) <p>15) <input type="checkbox"/> Notice of References Cited (PTO-892)</p> <p>16) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)</p> <p>17) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). <u>16</u></p> <p>18) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____</p> <p>19) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)</p> <p>20) <input checked="" type="checkbox"/> Other: <i>CRF Request letter attached</i></p>		

Art Unit: 1645

DETAILED ACTION

Request for Continued Examination

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/10/03 has been entered.

New Matter Rejection Overcome

2. Applicant's verified statement that the changes to the sequence listing and drawing recited in the Amendment filed 8/19/02, Paper No.11B, were of a clerical nature and/or a typographical nature on page 1 of that amendment and the verified statement in the Response submitted 6/10/03, Paper No. 15, that Applicants were in possession of this subject matter at the time of filing as the C-terminal region of the PAO pilin peptide was well-documented and known in the art at the time the invention was made sufficiently overcomes the former new matter rejection. This region of the polypeptide would remain intact and not be modified as the N-terminal portion. See Applicants' response of 6/10/03, Paper No. 15, for further support.

New CFR MUST be submitted:

3. Applicants have only submitted changes to the paper sequence listing. However, the electronic copy of the sequence listing must also be corrected. Applicant **must** submit a new

Art Unit: 1645

corrected electronic form/CRF to include the changes which includes the same changes which are being made to the paper listing.

APPLICANT IS GIVEN THE SAME TIME PERIOD FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. 1.821-

25. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Allowable Subject Matter

3. Claim 20 is allowed; however, a new CRF must be submitted in order for the application to be allowed.

4. Correspondence regarding this application should be directed to Group Art Unit 1641. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Group 1641 Fax number is (703) 308-4242 which is able to receive transmissions 24 hours/day, 7 days/week.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer E. Graser whose telephone number is (703) 308-1742. The examiner can normally be reached on Monday-Friday from 7:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached on (703) 308-3909.

Art Unit: 1645

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JGraser
JENNIFER E. GRASER
PRIMARY EXAMINER
6/16/07

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. A new CRF must be submitted which includes the amendment B.
Other:

Applicant must provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Atty Docket No. 113190-064	Application No. 09/865,159
	Applicant Irvin et al.	
	Filing Date 05-24-01	Group 1645

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner:

Date Considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.